IPP Bureau
AstraZeneca 1Q 2024 revenue up 19% to US$ 12,679 million
By IPP Bureau - April 27, 2024
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Takeda receives positive CHMP opinion for Fruquintinib in previously treated mCRC
By IPP Bureau - April 27, 2024
If approved in the European Union, Fruquintinib will be the first novel targeted therapy for Metastatic Colorectal Cancer regardless of biomarker status in over a decade
FDA approves Biktarvy label update with data for pregnant adults with HIV
By IPP Bureau - April 27, 2024
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
Divi's Laboratories to expand capacity at an outlay of approx. Rs. 700 Cr
By IPP Bureau - April 26, 2024
The proposed facility is expected to be operational around January, 2027
Dr. Reddy's and Nestle India to form JV for health science nutraceutical portfolio
By IPP Bureau - April 26, 2024
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Laurus Labs posts Q4 FY24 consolidated PAT at Rs. 75.61 Cr
By IPP Bureau - April 26, 2024
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
Merck 1Q 2024 sales up 9% to US$ 15.8 billion
By IPP Bureau - April 26, 2024
Sales reflect continued strong growth in oncology and vaccines
Syngene International reports Q4 FY24 consolidated PAT at Rs. 188.6 Cr
By IPP Bureau - April 25, 2024
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
Zydus Lifesciences gets 10 observations from USFDA for Jarod injectable facility
By IPP Bureau - April 25, 2024
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
New chemical method could cut waste from drug production
By IPP Bureau - April 25, 2024
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Bristol Myers Squibb and Cellares inks US$ 380 million capacity reservation for the manufacture of CAR T Cell Therapies
By IPP Bureau - April 23, 2024
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
AbbVie's phase 3 Select -GCA study of Upadacitinib showed positive results in patients with giant cell arteritis
By IPP Bureau - April 23, 2024
Open a printable version of this pageEmail the URL of this page to a friend
Voydeya approved in the EU as add-on treatment to ravulizumab
By IPP Bureau - April 23, 2024
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Zydus’ new drug application of Desidustat tablets accepted by China Medical System Holdings
By IPP Bureau - April 23, 2024
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Kwality Pharmaceuticals receives approval from INVIMA for Ampoule and Vial product lines
By IPP Bureau - April 23, 2024
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
